Literature DB >> 22016450

Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials.

Manuel Gomes1, Edmond S-W Ng1, Richard Grieve1, Richard Nixon2, James Carpenter3, Simon G Thompson4.   

Abstract

AIM: Cost-effectiveness analyses (CEAs) may use data from cluster randomized trials (CRTs), where the unit of randomization is the cluster, not the individual. However, most studies use analytical methods that ignore clustering. This article compares alternative statistical methods for accommodating clustering in CEAs of CRTs.
METHODS: Our simulation study compared the performance of statistical methods for CEAs of CRTs with 2 treatment arms. The study considered a method that ignored clustering--seemingly unrelated regression (SUR) without a robust standard error (SE)--and 4 methods that recognized clustering--SUR and generalized estimating equations (GEEs), both with robust SE, a "2-stage" nonparametric bootstrap (TSB) with shrinkage correction, and a multilevel model (MLM). The base case assumed CRTs with moderate numbers of balanced clusters (20 per arm) and normally distributed costs. Other scenarios included CRTs with few clusters, imbalanced cluster sizes, and skewed costs. Performance was reported as bias, root mean squared error (rMSE), and confidence interval (CI) coverage for estimating incremental net benefits (INBs). We also compared the methods in a case study.
RESULTS: Each method reported low levels of bias. Without the robust SE, SUR gave poor CI coverage (base case: 0.89 v. nominal level: 0.95). The MLM and TSB performed well in each scenario (CI coverage, 0.92-0.95). With few clusters, the GEE and SUR (with robust SE) had coverage below 0.90. In the case study, the mean INBs were similar across all methods, but ignoring clustering underestimated statistical uncertainty and the value of further research.
CONCLUSIONS: MLMs and the TSB are appropriate analytical methods for CEAs of CRTs with the characteristics described. SUR and GEE are not recommended for studies with few clusters.

Entities:  

Mesh:

Year:  2011        PMID: 22016450      PMCID: PMC3757919          DOI: 10.1177/0272989X11418372

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  46 in total

1.  Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation.

Authors:  A H Briggs; C Z Mooney; D E Wonderling
Journal:  Stat Med       Date:  1999-12-15       Impact factor: 2.373

2.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies.

Authors:  K Claxton
Journal:  J Health Econ       Date:  1999-06       Impact factor: 3.883

3.  Bayesian methods of analysis for cluster randomized trials with binary outcome data.

Authors:  R M Turner; R Z Omar; S G Thompson
Journal:  Stat Med       Date:  2001-02-15       Impact factor: 2.373

4.  Analysis of dichotomous outcome data for community intervention studies.

Authors:  S L Bellamy; R Gibberd; L Hancock; P Howley; B Kennedy; N Klar; S Lipsitz; L Ryan
Journal:  Stat Methods Med Res       Date:  2000-04       Impact factor: 3.021

5.  Analysis of a cluster randomized trial with binary outcome data using a multi-level model.

Authors:  R Z Omar; S G Thompson
Journal:  Stat Med       Date:  2000-10-15       Impact factor: 2.373

6.  Parametric modelling of cost data: some simulation evidence.

Authors:  Andrew Briggs; Richard Nixon; Simon Dixon; Simon Thompson
Journal:  Health Econ       Date:  2005-04       Impact factor: 3.046

7.  Bayesian hierarchical models for cost-effectiveness analyses that use data from cluster randomized trials.

Authors:  Richard Grieve; Richard Nixon; Simon G Thompson
Journal:  Med Decis Making       Date:  2009-08-12       Impact factor: 2.583

8.  Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC Trial of the Assessment and Management of Older People in the Community.

Authors:  Liam Smeeth; Edmond Siu-Woon Ng
Journal:  Control Clin Trials       Date:  2002-08

9.  Dangerous omissions: the consequences of ignoring decision uncertainty.

Authors:  Susan C Griffin; Karl P Claxton; Stephen J Palmer; Mark J Sculpher
Journal:  Health Econ       Date:  2011-02       Impact factor: 3.046

10.  Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study.

Authors:  Simon G Thompson; Richard M Nixon; Richard Grieve
Journal:  J Health Econ       Date:  2006-03-15       Impact factor: 3.883

View more
  52 in total

1.  Cost-effectiveness of integrated care in frail elderly using the ICECAP-O and EQ-5D: does choice of instrument matter?

Authors:  Peter Makai; Willemijn Looman; Eddy Adang; René Melis; Elly Stolk; Isabelle Fabbricotti
Journal:  Eur J Health Econ       Date:  2014-04-24

2.  Health Economic Evaluation Alongside Stepped Wedge Trials: A Methodological Systematic Review.

Authors:  Thomas Lung; Lei Si; Richard Hooper; Gian Luca Di Tanna
Journal:  Pharmacoeconomics       Date:  2020-10-05       Impact factor: 4.981

3.  A cost-effectiveness analysis of school-based suicide prevention programmes.

Authors:  Susan Ahern; Lee-Ann Burke; Brendan McElroy; Paul Corcoran; Elaine M McMahon; Helen Keeley; Vladimir Carli; Camilla Wasserman; Christina W Hoven; Marco Sarchiapone; Alan Apter; Judit Balazs; Raphaela Banzer; Julio Bobes; Romuald Brunner; Doina Cosman; Christian Haring; Michael Kaess; Jean-Pierre Kahn; Agnes Kereszteny; Vita Postuvan; Pilar A Sáiz; Peeter Varnik; Danuta Wasserman
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-02-14       Impact factor: 4.785

Review 4.  Review of Recent Methodological Developments in Group-Randomized Trials: Part 2-Analysis.

Authors:  Elizabeth L Turner; Melanie Prague; John A Gallis; Fan Li; David M Murray
Journal:  Am J Public Health       Date:  2017-05-18       Impact factor: 9.308

5.  Structured Pharmacist Review of Medication in Older Hospitalised Patients: A Cost-Effectiveness Analysis.

Authors:  James Gallagher; David O'Sullivan; Suzanne McCarthy; Paddy Gillespie; Noel Woods; Denis O'Mahony; Stephen Byrne
Journal:  Drugs Aging       Date:  2016-04       Impact factor: 3.923

6.  Long-term cost effectiveness of cardiac secondary prevention in primary care in the Republic of Ireland and Northern Ireland.

Authors:  Paddy Gillespie; Edel Murphy; Susan M Smith; Margaret E Cupples; Molly Byrne; Andrew W Murphy
Journal:  Eur J Health Econ       Date:  2016-03-09

7.  Cost-effectiveness of a faith-based lifestyle intervention for diabetes prevention among African Americans: A within-trial analysis.

Authors:  Elizabeth C Rhodes; Eeshwar K Chandrasekar; Shivani A Patel; K M Venkat Narayan; Thomas V Joshua; Lovoria B Williams; Lucy Marion; Mohammed K Ali
Journal:  Diabetes Res Clin Pract       Date:  2018-09-28       Impact factor: 5.602

8.  Point-of-care urine culture for managing urinary tract infection in primary care: a randomised controlled trial of clinical and cost-effectiveness.

Authors:  Christopher C Butler; Nick A Francis; Emma Thomas-Jones; Mirella Longo; Mandy Wootton; Carl Llor; Paul Little; Michael Moore; Janine Bates; Timothy Pickles; Nigel Kirby; David Gillespie; Kate Rumsby; Curt Brugman; Micaela Gal; Kerenza Hood; Theo Verheij
Journal:  Br J Gen Pract       Date:  2018-02-26       Impact factor: 5.386

9.  Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT.

Authors:  Howard Ring; James Howlett; Mark Pennington; Christopher Smith; Marcus Redley; Caroline Murphy; Roxanne Hook; Adam Platt; Nakita Gilbert; Elizabeth Jones; Joanna Kelly; Angela Pullen; Adrian Mander; Cam Donaldson; Simon Rowe; James Wason; Fiona Irvine
Journal:  Health Technol Assess       Date:  2018-02       Impact factor: 4.014

10.  Cost-Effectiveness Analysis of a Physician-Implemented Medication Screening Tool in Older Hospitalised Patients in Ireland.

Authors:  Gary L O'Brien; Denis O'Mahony; Paddy Gillespie; Mark Mulcahy; Valerie Walshe; Marie N O'Connor; David O'Sullivan; James Gallagher; Stephen Byrne
Journal:  Drugs Aging       Date:  2018-08       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.